Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers

Recently developed KRAS(G12C) inhibitory drugs are beneficial to lung cancer patients harboring KRAS(G12C) mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect antitumor im...

Descripción completa

Detalles Bibliográficos
Autores principales: Mugarza, Edurne, van Maldegem, Febe, Boumelha, Jesse, Moore, Christopher, Rana, Sareena, Llorian Sopena, Miriam, East, Philip, Ambler, Rachel, Anastasiou, Panayiotis, Romero-Clavijo, Pablo, Valand, Karishma, Cole, Megan, Molina-Arcas, Miriam, Downward, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299537/
https://www.ncbi.nlm.nih.gov/pubmed/35857848
http://dx.doi.org/10.1126/sciadv.abm8780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299537/
https://www.ncbi.nlm.nih.gov/pubmed/35857848
http://dx.doi.org/10.1126/sciadv.abm8780

Ejemplares similares